<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03114618</url>
  </required_header>
  <id_info>
    <org_study_id>ONCOTHROMB12-01</org_study_id>
    <nct_id>NCT03114618</nct_id>
  </id_info>
  <brief_title>A New Clinic-Genetic Risk Score for Predicting Venous Thromboembolic Events in Cancer Patient</brief_title>
  <acronym>ONCOTHROMB</acronym>
  <official_title>Genomic Predictors Indicating the Risk of Venous Thromboembolic Disease in Cancer Patients Treated in Outpatient Clinics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andres muñoz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Servicio de Oncología Médica. HGU Gregorio Marañón. Madrid</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Unitat de Genòmica de Malalties Complexes. Institut d'Investigació Sant Pau</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario La Paz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario Ramon y Cajal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario de Fuenlabrada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario Marqués de Valdecilla</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Complexo Hospitalario de Ourense</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Complejo Universitario Torrecárdenas, Almería</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gendiag</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ferrer inCode, S.L.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Unitat d'Hemostasia i Trombosi. Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sociedad Española de Trombosis y Hemostasia (SETH)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital General Universitario Gregorio Marañon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Venous thromboembolism (VTE) is a common disease in cancer patients and one of the major&#xD;
      causes of cancer-associated mortality. Risk for developing VTE increases when cancer patients&#xD;
      are receiving chemotherapy. Current risk scores for predicting cancer-associated VTE in&#xD;
      ambulatory patients had low/moderate discrimination and clinical sensitivity. These models&#xD;
      use clinical and biochemical parameters of the patient.&#xD;
&#xD;
      In the development of VTE genetics play a relevant role. The product Thrombo inCode (TiC)&#xD;
      assess VTE risk prediction by using a combination of a genetic risk score (GRS) and clinical&#xD;
      parameters from the patient. The investigators hypothesized that the GRS included in TiC&#xD;
      combined with clinical parameter some of them associated with cancer could be better&#xD;
      predicted by TiC than by current risk scores (Khorana score).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The working hypothesis of this study establishes that the risk of cancer patients suffering a&#xD;
      thromboembolic event is conditioned by individual genomic factors. The genes to be analyzed&#xD;
      have clearly demonstrated their relationship with thromboembolic disease in other clinical&#xD;
      contexts. This study is considered the initiation of a field of research in genomic risk&#xD;
      markers indicating a risk of thrombosis in cancer patients. The ultimate goal of the study is&#xD;
      to establish a clinic-genomic score for selecting patients with a high risk of suffering&#xD;
      thrombotic events who can benefit from guided thromboprophylaxis. Its secondary goal is to&#xD;
      prevent the adverse effects of ineffective therapies in other patients (low-risk patients not&#xD;
      requiring an anti-thrombotic prophylaxis).&#xD;
&#xD;
      The aim is to demonstrate the link between the clinic-genetic profile and the risk of&#xD;
      suffering thromboembolic events in the group of cancer patients. The working hypothesis&#xD;
      establishes that cancer patients who develop thrombotic events will have a higher score for&#xD;
      the thrombosis risk clinic-genetic profile than cancer patients not developing thromboembolic&#xD;
      events. The second aim is to analyse whether the thrombosis clinic-genetic risk score&#xD;
      improves the detection of patients at risk of suffering a thromboembolic event compared to&#xD;
      the Khorana predictive model routinely used (Khorana score).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Venous thromboembolism events</measure>
    <time_frame>During the 18 months of follow up</time_frame>
    <description>The development of venous thromboembolism will be registered</description>
  </primary_outcome>
  <enrollment type="Actual">406</enrollment>
  <condition>Venous Thromboembolism (Deep Vein Thrombosis or Pulmonary Embolism), Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      EDTA Blood sample&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study will include patients diagnosed with colorectal, esophago-gastric, pancreas or&#xD;
        lung cancer who have not previously been treated with chemotherapy or chemotherapy and&#xD;
        radiation therapy and are candidate for chemotherapy in outpatient setting&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients over 18 years of age.&#xD;
&#xD;
          -  Patients treated in outpatient clinics with a documented histological or cytological&#xD;
             diagnosis for non-microcytic lung, colorectal, pancreatic or esophago-gastric cancer&#xD;
             at an advanced stage, locally advanced or localized not previously treated with&#xD;
             systemic chemotherapy and/or radiation therapy who are candidate for chemotherapy in&#xD;
             outpatient setting.&#xD;
&#xD;
          -  Performance status 0-2.&#xD;
&#xD;
          -  Patients signing the study informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Life expectancy of less than 3 months.&#xD;
&#xD;
          -  Patients undergoing anti-coagulant treatment before the cancer diagnosis, for reasons&#xD;
             other than a venous thromboembolic event.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrés J. Muñoz Martín, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopsital General Universitario Gregorio Marañón</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Complejo Hospitalario Torrecárdenas</name>
      <address>
        <city>Almeria</city>
        <state>Almería</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Fuenlabrada</name>
      <address>
        <city>Fuenlabrada</city>
        <state>Madrid</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario la Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Orense</name>
      <address>
        <city>Orense</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <results_reference>
    <citation>Soria JM, Morange PE, Vila J, Souto JC, Moyano M, Trégouët DA, Mateo J, Saut N, Salas E, Elosua R. Multilocus genetic risk scores for venous thromboembolism risk assessment. J Am Heart Assoc. 2014 Oct 23;3(5):e001060. doi: 10.1161/JAHA.114.001060.</citation>
    <PMID>25341889</PMID>
  </results_reference>
  <results_reference>
    <citation>Rubio-Terrés C, Soria JM, Morange PE, Souto JC, Suchon P, Mateo J, Saut N, Rubio-Rodríguez D, Sala J, Gracia A, Pich S, Salas E. Economic analysis of thrombo inCode, a clinical-genetic function for assessing the risk of venous thromboembolism. Appl Health Econ Health Policy. 2015 Apr;13(2):233-42. doi: 10.1007/s40258-015-0153-x.</citation>
    <PMID>25652150</PMID>
  </results_reference>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>March 14, 2017</study_first_submitted>
  <study_first_submitted_qc>April 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2017</study_first_posted>
  <last_update_submitted>April 10, 2017</last_update_submitted>
  <last_update_submitted_qc>April 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital General Universitario Gregorio Marañon</investigator_affiliation>
    <investigator_full_name>Andres muñoz</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

